A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
Key facts
- Who runs it
- BioCryst Pharmaceuticals
- Where
- Chicago, Indianapolis, New Haven, Palo Alto, and San Diego, United StatesSee the 5 sitesAlso in 4 other countries, 7 sites
- Trial code
- NCT06539507
- EU 2025-521973-16-00
- U1111-1303-9510
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 76 people enrolled
- Started
- 26 Sept 2024
- Expected to end
- Feb 2027
- Type of study
- Interventional, 6 groups
- Treatments tested
- BCX17725
- Placebo
- Record updated
- 6 November 2026
Who can take part
- Age
- 12 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Male or non-pregnant, non-lactating female aged 18 to 55 years, inclusive (Parts 1 and 2), 18 to 65 years, inclusive (Part 3), or 12 to 65 years, inclusive (Part 4)
- Confirmed diagnosis of Netherton syndrome (Parts 3 and 4)
- IGA score of ≥ 3 (Parts 3 and 4) and IASI score of ≥ 16 (Part 4)
- BMI between 18 and 30 kg/m\^2, inclusive (Parts 1 and 2)
- Estimated glomerular filtration rate (eGFR) of ≥ 90 mL/min/1.73 m\^2 (Parts 1 and 2) or ≥ 60 mL/min/1.73 m\^2 (Part 3)
- Agree to follow the protocol contraception requirements from screening until 90 days after the last dose of study drug
- In the opinion of the investigator, expected to adequately comply with all required study procedures and restrictions for the duration of the study
Where in United States
Also in 4 other countries, 7 sites
- Northwestern Dermatology CTUChicago, United States
- Dawes Fretzin Clinical Research Group, LLCIndianapolis, United States
- Yale Center for Clinical InvestigationNew Haven, United States
- Stanford University, School of MedicinePalo Alto, United States
- Therapeutics Clinical ResearchSan Diego, United States
About the trial
What the trial wants to find out
This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.
The 6 groups in the trial
- Part 1 - BCX17725 single doseTreatment being tested
Participants randomized to BCX17725 will receive BCX17725 as a single dose in sequential ascending dose cohorts
Treatment: BCX17725
- Part 1 - placebo single doseTreatment being tested
Participants randomized to placebo will receive placebo as a single dose
Treatment: Placebo
- Part 2 - BCX17725 multiple dosesTreatment being tested
Participants randomized to BCX17725 will receive BCX17725 as multiple doses in sequential ascending dose cohorts
Treatment: BCX17725
- Part 2 - placebo multiple dosesTreatment being tested
Participants randomized to placebo will receive placebo as multiple doses
Treatment: Placebo
- Part 3 - BCX17725 multiple dosesTreatment being tested
Participants will receive BCX17725 as multiple doses
Treatment: BCX17725
- Part 4 - BCX17725 multiple dosesTreatment being tested
Participants will receive BCX17725 as multiple doses
Treatment: BCX17725
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome
- Record updated
- 6 November 2026